Reply to "Pharmacological inhibition of ATGL as therapeutic approach for MASH: Far beyond the lipase suppression role of ATGL inhibitors"

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-03-05 DOI:10.1016/j.jhep.2025.02.022

Emmanuel Dauda Dixon, Thierry Claudel, Michael Trauner

{"title":"Reply to \"Pharmacological inhibition of ATGL as therapeutic approach for MASH: Far beyond the lipase suppression role of ATGL inhibitors\"","authors":"Emmanuel Dauda Dixon, Thierry Claudel, Michael Trauner","doi":"10.1016/j.jhep.2025.02.022","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Acknowledgements</h2>EDD: initial drafting of the manuscript. TC: revision of the manuscript. MT: conception and revision and final approval of the manuscript. All the authors approved the final version of the letter.</section></section><section><section><h2>Authors' contributions</h2>Arial, normal, 12</section></section><section><section><h2>Financial support</h2>This work was supported by the Austrian Science Fund FWF (SFB F73 [F7301]), the County of Styria, and the City of Graz.</section></section><section><section><h2>Declaration of Competing Interest</h2>MT has received research grants from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and Ultragenyx and travel grants from Abbvie, Falk, Gilead Intercept and Jannsen. He further has advised for Abbvie, Agomab, Albireo, Agomab, BiomX, Boehringer Ingelheim, Chemomab Falk Pharma GmbH, Genfit, Gilead, Hightide, Intercept, Ipsen, Janssen, MSD, Mirum, Novartis, Phenex, Pliant, Regulus, Siemens and Shire and has served as speaker for Albireo, BMS, Boehringer Ingelheim, Falk,</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"35 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2025.02.022","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Acknowledgements

EDD: initial drafting of the manuscript. TC: revision of the manuscript. MT: conception and revision and final approval of the manuscript. All the authors approved the final version of the letter.

Authors' contributions

Arial, normal, 12

Financial support

This work was supported by the Austrian Science Fund FWF (SFB F73 [F7301]), the County of Styria, and the City of Graz.

Declaration of Competing Interest

MT has received research grants from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and Ultragenyx and travel grants from Abbvie, Falk, Gilead Intercept and Jannsen. He further has advised for Abbvie, Agomab, Albireo, Agomab, BiomX, Boehringer Ingelheim, Chemomab Falk Pharma GmbH, Genfit, Gilead, Hightide, Intercept, Ipsen, Janssen, MSD, Mirum, Novartis, Phenex, Pliant, Regulus, Siemens and Shire and has served as speaker for Albireo, BMS, Boehringer Ingelheim, Falk,

查看原文本刊更多论文

回复“ATGL的药理抑制作为治疗MASH的方法：远远超出ATGL抑制剂的脂肪酶抑制作用”

Section snippetsAcknowledgementsEDD：初稿。TC：修改原稿。MT：构思、修改和最终审定稿件。所有的作者都认可了这封信的最终版本。本研究得到了奥地利科学基金FWF （SFB F73 [F7301]）、施蒂里亚县和格拉茨市的支持。mt已获得Albireo、Alnylam、Cymabay、Falk、Genentech、Gilead、Intercept、MSD、武田和Ultragenyx的研究资助，以及Abbvie、Falk、Gilead Intercept和Jannsen的旅行资助。他还曾为Abbvie、Agomab、Albireo、Agomab、BiomX、Boehringer Ingelheim、Chemomab Falk Pharma GmbH、Genfit、Gilead、Hightide、Intercept、Ipsen、Janssen、MSD、Mirum、Novartis、Phenex、Pliant、Regulus、Siemens和Shire提供咨询服务，并曾担任Albireo、BMS、Boehringer Ingelheim、Falk、

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.